FPO IMPROVED QUALITY METRICS ARE WITHIN REACH We can do better. 73% of US patients with diabetes are not meeting targets for glycemic, blood pressure or cholesterol control1 and less than 7% are tested at the guideline-recommended frequency for HbA1c.2 Coaching and compliance are key. HbA1c testing at the point of care (POC) allows clinicians to better achieve ADA guidelines. Data shows patients who are managed in compliance with the guidelines are over 5 times more likely to achieve a recommended HbA1c under 7%.2 Afinion™ 2 is the market leader in CLIA-waived HbA1c testing. With highly accurate results in as little as 3 minutes, clinicians can more easily manage patients according to ADA guidelines at the POC, achieving improved quality metrics and better patient outcomes. REFERENCES: 1. Ali MK, Bullard KM, Gregg EW, del Rio C. Ann Intern Med. 2014;161(10):681-9. 2. J. Lian, et al. Curr Med Res Opin. 2014;30(11):2233-40. ©202 Abbott. All rights reserved. COL-195704 Contact your Henry Schein Sales Representative or scan the QR code for more information about the Afinion 2™ analyzer. 42 henryschein.com/sm 24SM2615http://www.henryschein.com/sm